Christophe Przybylski

Title: Christophe Przybylski: Innovator in Cognitive Health

Introduction

Christophe Przybylski is a notable inventor based in Villefranche de Lauragais, France. He has made significant contributions to the field of cognitive health, particularly through his innovative patents. With a total of 2 patents, Przybylski's work focuses on treatments for mild cognitive impairment and urinary incontinence.

Latest Patents

Przybylski's latest patents include a groundbreaking invention involving dimethylaminoethanol (DMAE) as a sole active ingredient for treating mild cognitive impairment. This invention emphasizes the use of DMAE in free form or as salts, esters, hydrates, and solvates for the manufacture of a medicament aimed at non-dementia mild cognitive impairment characterized by an amnestic syndrome of hippocampal type. Another significant patent relates to the use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine and its pharmaceutically acceptable salts for preparing a drug that treats or prevents urinary incontinence via local and/or oral routes.

Career Highlights

Throughout his career, Przybylski has worked with prominent companies in the pharmaceutical industry, including Pierre Fabre Medicament and Pierre Fabre Dermo-Cosmetique. His experience in these organizations has contributed to his expertise in developing innovative medical solutions.

Collaborations

Przybylski has collaborated with notable professionals in his field, including Bruno Dubois and Thierry Clerc. These collaborations have further enriched his work and expanded the impact of his inventions.

Conclusion

Christophe Przybylski stands out as an influential inventor in the realm of cognitive health, with his patents paving the way for new treatments. His dedication to innovation continues to make a significant impact in the medical field.